Hi MindBio is pleased to report it has completed its 6-month milestone post treatment with MB22001 in a Phase 2A microdosing depression trial and will be releasing the data in the coming fortnight.Photo: Justin Hanka, MindBio CEO and Co-Founder insp...

Hi MindBio is pleased to report on long term stability data for its lead candidate drug MB22001. These stability findings, are an important part of our commercialisation journey, to produce medicines that can be stored and used safely for long perio...

Hi Join me as I discuss MindBio's landmark take-home microdosing clinical trial in patients with Major Depressive Disorder as we enter our 25th participant into this randomized, triple blind, double dummy, active placebo controlled trial.Click to Wat...

Hi I'm pleased to present a brief video update on whats happening at MindBio.We recently reported a sustained anti-depressant response from microdosing MB220001 at 1 months and 3 months post cessation of an 8-week treatment cycle. Our women's health...

Hi We continue take-home dosing in two Phase 2B clinical trials with a third Phase 2B women's health trial recently approved for use of a microdose of a psychedelic medicine (MB22001) to treat mood symptoms in Premenstrual Syndrome and Premenstrual D...

Hi Please see release from MindBio Therapeutics below.Vancouver, British Columbia – July 8, 2024 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a leading biopharmaceutical company in psychiatric microdosing me...

Hi We are pleased to present secondary data from MindBio's Phase 2A Microdosing Depression Trial completed earlier this year.Data from MindBio’s Phase 2A Depression trial indicates improvements in a range of secondary outcome measures following an 8-...

Hi Please see latest news release posted today from MindBio and Enveric Biosciences.Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders.M...

Hi The impact of under-representation of women in clinical trials is significant and has resulted in an over-representation of serious adverse events and side effects from prescribed medications in women.Tune into Dr Rachael Sumner, who discusses the...

Hi We are progressing this worthwhile clinical research in multiple Phase 2B trials and setting the company up for it's future. Read MoreNEWS RELEASEMINDBIO EXPLORES DUAL LISTING ON A SENIOR EXCHANGE WITH MULTIPLE PHASE 2B CLINICAL TRIALS UNDERWAY SU...